REPLIGEN CORP (RGEN)
US7599161095 - Common Stock
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 58 industry peers in the Life Sciences Tools & Services industry. RGEN has an average financial health and profitability rating. While showing a medium growth rate, RGEN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
In the past year RGEN had a positive cash flow from operations.
Each year in the past 5 years RGEN has been profitable.
In the past 5 years RGEN always reported a positive cash flow from operatings.
1.2 Ratios
RGEN has a Return On Assets of 0.52%. This is in the better half of the industry: RGEN outperforms 70.18% of its industry peers.
RGEN has a better Return On Equity (0.76%) than 71.93% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.07%, RGEN is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for RGEN is below the industry average of 10.00%.
The last Return On Invested Capital (0.07%) for RGEN is well below the 3 year average (5.35%), which needs to be investigated, but indicates that RGEN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 0.76% | ||
| ROIC | 0.07% |
ROA(3y)4.76%
ROA(5y)3.79%
ROE(3y)6.39%
ROE(5y)5.02%
ROIC(3y)5.35%
ROIC(5y)4.31%
1.3 Margins
With a decent Profit Margin value of 2.45%, RGEN is doing good in the industry, outperforming 70.18% of the companies in the same industry.
RGEN's Profit Margin has declined in the last couple of years.
RGEN's Operating Margin of 0.40% is fine compared to the rest of the industry. RGEN outperforms 63.16% of its industry peers.
In the last couple of years the Operating Margin of RGEN has declined.
With a Gross Margin value of 44.00%, RGEN perfoms like the industry average, outperforming 49.12% of the companies in the same industry.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.4% | ||
| PM (TTM) | 2.45% | ||
| GM | 44% |
OM growth 3Y-12.31%
OM growth 5Y-1.83%
PM growth 3Y-26.44%
PM growth 5Y-5.32%
GM growth 3Y-4.81%
GM growth 5Y-2.29%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
Compared to 1 year ago, RGEN has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.89 indicates that RGEN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.89, RGEN belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.
RGEN has a debt to FCF ratio of 5.33. This is a neutral value as RGEN would need 5.33 years to pay back of all of its debts.
The Debt to FCF ratio of RGEN (5.33) is better than 73.68% of its industry peers.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
RGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.33 | ||
| Altman-Z | 5.89 |
ROIC/WACC0.01
WACC12.02%
2.3 Liquidity
A Current Ratio of 6.35 indicates that RGEN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.35, RGEN is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
RGEN has a Quick Ratio of 5.24. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN's Quick ratio of 5.24 is fine compared to the rest of the industry. RGEN outperforms 77.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.35 | ||
| Quick Ratio | 5.24 |
3. Growth
3.1 Past
The earnings per share for RGEN have decreased strongly by -54.33% in the last year.
The Earnings Per Share has been growing by 18.51% on average over the past years. This is quite good.
The Revenue for RGEN has decreased by -21.90% in the past year. This is quite bad
Measured over the past years, RGEN shows a very strong growth in Revenue. The Revenue has been growing by 26.91% on average per year.
EPS 1Y (TTM)-54.33%
EPS 3Y1.39%
EPS 5Y18.51%
EPS Q2Q%-56.25%
Revenue 1Y (TTM)-21.9%
Revenue growth 3Y20.37%
Revenue growth 5Y26.91%
Sales Q2Q%-17.16%
3.2 Future
Based on estimates for the next years, RGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.99% on average per year.
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 14.84% on average per year.
EPS Next Y-14.26%
EPS Next 2Y8.81%
EPS Next 3Y14.99%
EPS Next 5YN/A
Revenue Next Year-0.31%
Revenue Next 2Y7.33%
Revenue Next 3Y10.58%
Revenue Next 5Y14.84%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 102.77, the valuation of RGEN can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN indicates a somewhat cheap valuation: RGEN is cheaper than 63.16% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 24.41. RGEN is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 68.74, which means the current valuation is very expensive for RGEN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 20.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 102.77 | ||
| Fwd PE | 68.74 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 71.87 | ||
| EV/EBITDA | 99.94 |
4.3 Compensation for Growth
The decent profitability rating of RGEN may justify a higher PE ratio.
RGEN's earnings are expected to grow with 14.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)5.55
EPS Next 2Y8.81%
EPS Next 3Y14.99%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPLIGEN CORP
NASDAQ:RGEN (7/26/2024, 7:00:01 PM)
After market: 140.79 0 (0%)140.79
+8.43 (+6.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.87B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 102.77 | ||
| Fwd PE | 68.74 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)5.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 0.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 0.4% | ||
| PM (TTM) | 2.45% | ||
| GM | 44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.35 | ||
| Quick Ratio | 5.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-54.33%
EPS 3Y1.39%
EPS 5Y
EPS Q2Q%
EPS Next Y-14.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.9%
Revenue growth 3Y20.37%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y